BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

NCT07118358 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 325

Last updated 2026-04-06

No results posted yet for this study

Summary

The objective of this Investigational Device Exemption trial is to confirm the safety and performance of the LivIQ leadless pacemaker system, in patients with a Class I or II indication for ventricular pacing (VVI/VDD) according to applicable guidelines. An integrated atrioventricular synchrony sub-study (AVS) is specifically designed to evaluate the AVS performance of the LivIQ system.

Conditions

  • Leadless Pacemaker
  • Bradycardia
  • AV Block
  • Cardiac Rhythm Disorder

Interventions

DEVICE

LivIQ Leadless Pacemaker System

Patients will receive a single-chamber leadless pacemaker system, with the device implanted directly into the right ventricle.

Sponsors & Collaborators

  • Biotronik SE & Co. KG

    collaborator INDUSTRY
  • Biotronik Japan, Inc.

    collaborator INDUSTRY
  • Biotronik Australia Pty Ltd.

    collaborator INDUSTRY
  • Biotronik, Inc.

    lead INDUSTRY

Principal Investigators

  • Samuel Asirvatham, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-16
Primary Completion
2027-03-31
Completion
2028-04-30
FDA Device
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07118358 on ClinicalTrials.gov